APM
ELVN icon

Avidity Partners Management’s Enliven Therapeutics ELVN Stock Holding History

Avidity Partners Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Sell
550,000
-250,000
-31% -$10.6M 4.47% 5
2026
Q1 		$32.2M Buy
800,000
+659,700
+470% +$18.3M 3.44% 6
2025
Q4 		$2.16M Hold
140,300
– – 0.62% 33
2025
Q3 		$2.87M Buy
140,300
+129,000
+1,142% +$2.6M 0.65% 34
2025
Q2 		$227K Hold
11,300
– – 0.05% 55
2025
Q1 		$222K Buy
+11,300
New +$243K 0.04% 65

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Avidity Partners Management's ELVN Position: Q2 2026 in Review

Avidity Partners Management reduced its Enliven Therapeutics (ELVN) stake by 31% in Q2 2026, selling an estimated $10.6M and leaving 550,000 shares worth $27.9M. The position accounts for 4.47% of the portfolio, ranked #5.

Avidity Partners Management first reported a position in ELVN in Q1 2025 and has held it in 6 quarters since. The position peaked at $32.2M in Q1 2026. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Avidity Partners Management held 550,000 shares of Enliven Therapeutics worth $27.9M as of Q2 2026.
  • Avidity Partners Management sold 250,000 Enliven Therapeutics shares in Q2 2026, an estimated $10.6M.
  • Enliven Therapeutics made up 4.47% of Avidity Partners Management's portfolio in Q2 2026, its #5 holding.
  • Avidity Partners Management first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Avidity Partners Management's Enliven Therapeutics position peaked at $32.2M in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.